CO162 A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients with Metastatic Renal Cell Carcinoma in Latin America

M. Jimenez, G. Zanotti,R.C. Parikh,E. Esterberg, L.A. Suarez

Value in Health（2023）

引用 0|浏览6

暂无评分

摘要

To assess clinical outcomes among patients with metastatic renal cell carcinoma (mRCC) in Latin America who switched from the 4/2 (4 weeks on/2 weeks off) to the 2/1 (2 weeks on/1 week off) schedule of first-line sunitinib.

查看译文

关键词

metastatic renal cell carcinoma,first-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要